JVM Q3 Operating Profit Hits KRW 9.9 Billion, Up 30% YoY

Revenue of KRW 40.5 billion, net profit of KRW 9.6 billion
Shipments of high-margin equipment to North America increase

JVM, a pharmaceutical automated dispensing equipment company affiliated with Hanmi Science, significantly improved its profitability in the third quarter. The improvement was driven by increased shipments of high-margin equipment to North America, along with favorable exchange rates and a lower cost ratio.

On October 30, JVM announced that its third-quarter consolidated revenue was KRW 40.5 billion and operating profit was KRW 9.9 billion. Net profit totaled KRW 9.6 billion. Compared with the same period last year, revenue increased 2.1%, operating profit rose 30.4%, and net profit climbed 49.9%. Domestic sales accounted for 51.6% of revenue and overseas sales for 48.4%. Overseas revenue comprised 21.5% from Europe, 19.1% from North America, and 7.8% from other regions.

The North American market led the improvement in profitability. Revenue in North America increased 37.9% from the same period last year. Shipments of high-margin products, including the COUNTMATE pill counter and automated tablet dispensing, packaging, and inspection systems (ATDPS), increased, while favorable exchange rates and an improved cost ratio also contributed. Total export revenue rose 5.1%.

JVM is also strengthening its overseas production and sales base. Its production subsidiary in Suzhou, China, began local production and sales and recorded its first revenue. In Europe, the company secured a new sales channel by partnering with a local company in the United Kingdom. JVM plans to lend €5 million in operating funds to its European subsidiary, JVM Europe B.V., over four years, from next month through November 2030.

JVM is also pursuing shareholder returns. The company will cancel 70% of its 552,903 treasury shares, or 4.57% of its total shares outstanding, equivalent to 387,032 shares. The remaining 30%, or 165,871 shares, will be used for employee share-based compensation.

“As the dispensing environment changes rapidly, demand is growing for efficient dispensing systems based on automation and robotics,” said Kim Sang-wook, CEO of JVM. “With the introduction of MENIS in Korea for the first time as a starting point, we will expand into new business opportunities and strengthen our competitiveness as a global pharmaceutical dispensing automation company through research and development and the launch of new products.”

This content was produced with the assistance of AI translation services.